Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented BioAge Labs in the transaction. BioAge Labs (BioAge) announced it completed the oversubscribed $170M Series D financing round led by Sofinnova Investments...
You must be a Standard 1 Year member to access this content.
Fenwick & West and Sidley Austin are representing Impel Pharmaceuticals Inc. in the transaction. JN BIDCO LLC announced the acquisition of Impel Pharmaceuticals Inc. (OTCQX: IMPL)....
You must be a Standard 1 Year member to access this content.
Fenwick represented Scribe Therapeutics on the deal. Scribe Therapeutics, a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, announced its strategic collaboration and...
You must be a Standard 1 Year member to access this content.
Fenwick & West LLP advised Impel NeuroPharma on the deal. Impel NeuroPharma, a late-stage pharmaceutical company developing transformative therapies for diseases of the central nervous system, announced its...
You must be a Standard 1 Year member to access this content.
